Lean-mass protection while cutting
One of 6 mechanistic pathways to 🔥 Lose fat · 13 options
Fat loss that takes muscle with it lowers your metabolic rate and guarantees the regain. Any aggressive deficit — and every GLP-1 — needs an answer to this, and it belongs in the fat-loss plan rather than as an afterthought once the scale has moved.
Muscle loss on an aggressive deficit is invisible on the scale and obvious in IGF-1 and testosterone, both of which fall in a sustained deficit. Worth a baseline before you start and a recheck at eight weeks — this is the panel built specifically for people running a GLP-1.
IGF-1 (Insulin-like Growth Factor 1)Total TestosteroneFree TestosteroneComprehensive Metabolic Panel (CMP)💉 On a GLP-1 (Semaglutide / Tirzepatide) covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Tesamorelin
A GHRH analog with actual trial evidence for reducing visceral adipose tissue specifically, while raising IGF-1 enough to defend lean mass. The most target-specific fat compound in the Vault.
💉 CJC-1295 No Dac
Pulsatile GH release preserves the physiological rhythm. GH is lipolytic and anti-catabolic; the prediction in a deficit is retained lean tissue and better recovery.
💉 Ipamorelin
A selective GH secretagogue with minimal cortisol or prolactin spill. The low-side-effect argument is why it's the default partner for a cutting stack.
💉 CJC No Dac/Ipamorelin
GHRH plus ghrelin-mimetic together produce a larger GH pulse than either alone — genuine synergy rather than additive dosing.
💉 Sermorelin
The gentlest GHRH analog, closest to physiological signalling. Weakest effect, best safety argument.
💉 Bimagrumab
An activin type-II receptor antibody. In human trials it produced the cleanest body-recomposition signal on record — substantial fat loss with lean-mass GAIN — and it is now being trialled specifically as a GLP-1 partner to fix their muscle-loss problem.
💉 Follistatin 344
Binds and neutralises myostatin. Mechanistically the muscle-preservation argument in a deficit is strong; human data is basically absent and the delivery problem is unsolved.
💉 ACE-083
A locally-acting follistatin-based myostatin trap designed for injection into a specific muscle. Produced local hypertrophy in humans but failed to improve function in its trials.
🧬 Whey Protein (RecoveryPro)
Leucine content and absorption kinetics make it the most reliable acute stimulus for muscle protein synthesis available. Adequate protein is the single largest lever in this pathway and it is not a peptide.
🧬 Essential Amino Acids
Supplies the nine amino acids that must come from diet. Useful when total protein intake is genuinely restricted.
🧬 HMB
A leucine metabolite that reduces proteolysis. The evidence is best in catabolic states — aggressive deficits, illness, detraining — and weak in well-fed trained lifters.
🧬 Creatine
The most evidence-backed supplement in existence. Preserves strength and cell volume through a deficit; ATP resynthesis is unaffected by dieting.
🧬 L-Glutamine
Conditionally essential under metabolic stress. The anti-catabolic case is better in clinical illness than in dieting athletes.
The other 5 routes to lose fat
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
Want the protocols behind these?
Dosing schedules, stacking, cycle timing and Coach Cam's notes live inside the Academy — plus the full interactive Vault.
Join the Academy — $10/mo →← Open this pathway in the interactive Vault
Frequently asked questions
Fat loss that takes muscle with it lowers your metabolic rate and guarantees the regain. Any aggressive deficit — and every GLP-1 — needs an answer to this, and it belongs in the fat-loss plan rather than as an afterthought once the scale has moved.
13 options are mapped to this pathway in the Vault, including Tesamorelin, CJC-1295 No Dac, Ipamorelin, CJC No Dac/Ipamorelin. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 7 carry clinical validation and 6 are mechanistic predictions.
Muscle loss on an aggressive deficit is invisible on the scale and obvious in IGF-1 and testosterone, both of which fall in a sustained deficit. Worth a baseline before you start and a recheck at eight weeks — this is the panel built specifically for people running a GLP-1. The markers worth checking are IGF-1 (Insulin-like Growth Factor 1), Total Testosterone, Free Testosterone, Comprehensive Metabolic Panel (CMP).
Unproven is not the same as ineffective. Of the 13 options on this pathway, 7 have clinical validation and 6 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.